<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156580</url>
  </required_header>
  <id_info>
    <org_study_id>2021-P2-163-01</org_study_id>
    <nct_id>NCT05156580</nct_id>
  </id_info>
  <brief_title>Tongzhou Cohort Study</brief_title>
  <official_title>Cardiovascular Risk in Elderly Obese Patients With Hypertension During Rapid Urbanization of Tongzhou District: A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tongzhou Yongshun Community Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aimed to investigate the impact of obesity on long-term cardiovascular risk&#xD;
      in elderly patients with hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overweight status and obesity are important risk factors leading to hypertension, poor blood&#xD;
      pressure control, and poor prognosis. However, the studies focused on elderly patients with&#xD;
      hypertension are limited. Therefore, the aim of the present study was to evaluate the&#xD;
      long-term impact of obesity on cardiovascular risk in elderly patients with hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with major adverse cardiovascular events (MACEs)</measure>
    <time_frame>2021-2026</time_frame>
    <description>Percentage of participants with major adverse cardiovascular events (MACEs), including all-cause death, nonfatal myocardial infarction (MI), nonfatal stroke and coronary revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with all-cause death</measure>
    <time_frame>2021-2026</time_frame>
    <description>Percentage of participants with cardiovascular, non-cardiovascular and undetermined death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with MI</measure>
    <time_frame>2021-2026</time_frame>
    <description>Percentage of participants with fatal and nonfatal MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with stroke</measure>
    <time_frame>2021-2026</time_frame>
    <description>Percentage of participants with fatal and nonfatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants undergoing coronary revascularization</measure>
    <time_frame>2021-2026</time_frame>
    <description>Percentage of participants undergoing ischemia- and non-ischemia-driven coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BP control rate</measure>
    <time_frame>2021-2026</time_frame>
    <description>Change in BP control rate (office BP: SBP &lt; 140 mmHg and DBP &lt; 90 mmHg) from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP</measure>
    <time_frame>2021-2026</time_frame>
    <description>Change in SBP from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>2021-2026</time_frame>
    <description>Change in estimated glomerular filtration rate (eGFR) in ml/min/1.73m2 from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in low-density lipoprotein-cholesterol (LDL-c)</measure>
    <time_frame>2021-2026</time_frame>
    <description>Change in low-density lipoprotein-cholesterol (LDL-c) in mmol/L from baseline to follow-up.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">6500</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Obese hypertensive group</arm_group_label>
    <description>Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight hypertensive group</arm_group_label>
    <description>Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean hypertensive group</arm_group_label>
    <description>Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study without any intervention</description>
    <arm_group_label>Lean hypertensive group</arm_group_label>
    <arm_group_label>Obese hypertensive group</arm_group_label>
    <arm_group_label>Overweight hypertensive group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with hypertension in Tongzhou, China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages of ≥ 60 years&#xD;
&#xD;
          -  History of hypertension and treatment with anti-hypertension drugs for more than 4&#xD;
             weeks&#xD;
&#xD;
          -  Availability for follow-up until 2026&#xD;
&#xD;
          -  No major barriers to provide written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongchong Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rongchong Huang, M.D.</last_name>
    <phone>+86-13811039417</phone>
    <email>rchuang@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongchong Huang, M.D.</last_name>
      <phone>+86-13811039417</phone>
      <email>rchuang@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Rongchong Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

